DSpace width= university logo mark
Japanese | English 

KURA > C. 医薬保健学域・研究域/医・薬学部/医学系研究科 > c10. 学術雑誌掲載論文(医・保健) > 1. 査読済論文(医学・保健) >


ファイル 記述 サイズフォーマット
ME-PR-KOBAYASHI-J-712.pdf168.59 kBAdobe PDF
タイトル: Serum lipoprotein lipase mass: Clinical significance of its measurement
著者: Kobayashi, Junji link image
Nohara, Atsushi link image link image
Kawashiri, Masaaki link image link image
Inazu, Akihiro link image link image
Koizumi, Junji link image
Nakajima, Katsuyuki
Mabuchi, Hiroshi link image
小林, 淳二
野原, 淳
小泉, 順二
馬渕, 宏
発行日: 2007年 3月
出版社(者): Elsevier BV
引用: Clinica Chimica Acta 378(1-2), pp.7-12
雑誌名: Clinica Chimica Acta
ISSN: 0009-8981
巻: 378
号: 1-2
開始ページ: 7
終了ページ: 12
キーワード: Atherosclerosis
Carotid artery
Coronary artery
Visceral fat
抄録: Lipoprotein lipase (LPL) is a lipolytic enzyme involved in catalyzing hydrolysis of triglycerides (TG) in chylomicrons and very low-density lipoprotein (VLDL) particles. Over the last decade, increasing attention has been paid to the clinical significance of measuring serum LPL protein mass without heparin injection to the study subjects. In earlier studies, this marker was utilized to classify LPL deficient subjects, which is an extremely rare metabolic disorder with a frequency of one in one million. Later, researchers paid more attention to the clinical significance of measuring this parameter in more common metabolic disorders. Studies have shown that pre-heparin plasma or serum LPL mass has significant relationships with serum lipids and lipoproteins, visceral fat area, insulin resistance, and even the development of coronary atherosclerosis in cross-sectional studies, although this might be a metabolic surrogate marker with almost no catalytic activities, which does not appear to be involved in catalyzing hydrolysis of TG in TG-rich lipoproteins. Recently, a prospective study has demonstrated that low serum LPL concentration predicts future coronary events. Taken together, we suggest that pre-heparin LPL mass in plasma or sera provide us with useful and important information on the development of metabolic disorders leading to atherosclerotic disease. © 2006 Elsevier B.V. All rights reserved.
URI: http://hdl.handle.net/2297/3653
関連URI: http://dx.doi.org/10.1016/j.cca.2006.12.003
資料種別: Journal Article
版表示: author
出現コレクション:1. 査読済論文(医学・保健)

このアイテムを引用あるいはリンクする場合は次の識別子を使用してください。 http://hdl.handle.net/2297/3653



Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - ご意見をお寄せください